Knight Therapeutics (TSE:GUD) Hits New 52-Week High – Here’s Why

Knight Therapeutics Inc. (TSE:GUD)’s stock price hit a new 52-week high during trading on Friday. The company traded as high as C$11.09 and last traded at C$11.04, with a volume of 48,763 shares changing hands. The stock had previously closed at C$10.80.

Knight Therapeutics Trading Up 2.2%

The firm has a market cap of C$1.08 billion, a PE ratio of 73.60, a P/E/G ratio of -1,013.50 and a beta of -0.45. The company has a current ratio of 2.28, a quick ratio of 1.79 and a debt-to-equity ratio of 4.29. The business has a fifty day moving average price of C$10.05 and a 200 day moving average price of C$9.20.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings data on Thursday, August 6th. The company reported C($0.03) earnings per share for the quarter. Knight Therapeutics had a return on equity of 1.91% and a net margin of 2.72%. The company had revenue of C$143.97 million for the quarter. Analysts forecast that Knight Therapeutics Inc. will post 0.10 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc, headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc’s shares trade on the TSX under the symbol GUD. For more information about Knight Therapeutics Inc, please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.